Obesity Pharmacotherapy: Current Perspectives and Future Directions

Dr. Monika Misra*

Department of Pharmacology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh: 202002, India

Abstract: The rising tide of obesity and its related disorders is one of the most pressing health concerns worldwide, yet existing medicines to combat the problem are disappointingly limited in number and effectiveness. Recent advances in mechanistic insights into the neuroendocrine regulation of body weight have revealed an expanding list of molecular targets for novel, rationally designed antiobesity pharmaceutical agents. Antiobesity drugs act via any of four mechanisms: 1) decreasing energy intake, 2) increasing energy expenditure or modulating lipid metabolism, 3) modulating fat stores or adipocyte differentiation, and 4) mimicking caloric restriction. Various novel drug candidates and targets directed against obesity are currently being explored. A few of them are also in the later phases of clinical trials. This review discusses the development of novel antiobesity drugs based on current understanding of energy homeostasis.

Keywords: Obesity, Pharmacotherapy, Drug targets.

INTRODUCTION

Obesity has progressed to epidemic proportions globally, with more than 1.6 billion adults overweight and at least 400 million of them clinically obese [1]. It is a leading contributor to the global burden of chronic diseases like type 2 diabetes, cardiovascular disease, hypertension, stroke, and certain forms of cancer. The health outcomes range from increased risk of premature death to serious chronic conditions that reduce the overall quality of life [1]. Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2].

According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, “weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of ≥30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of ≥27 with concomitant obesity-related risk factors or diseases”[3]. The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27–29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]. In 2007–2008, the prevalence of American adults having a BMI greater than 30 was 32.2% among men and 35.5% among women [4]. In light of the NIH guidelines, this startling preponderance of obesity indicates pharmacotherapy is warranted for more than one-third of all American adults. Yet, existing medicines to combat the problem are disappointingly few in number and efficacy. In the past few years, understanding of the mechanisms involved in regulating feeding behavior and energy expenditure has evolved considerably, and targeting these mechanisms for drug development has garnered greater attention as well. This review discusses the neuroendocrine control of energy homeostasis, drug targets, and the possible future range of anti-obesity agents.

PATHOPHYSIOLOGY OF OBESITY

The etiology of obesity is complex. Genetic, environmental, and psychological factors are implicated in its causation. Obesity is a disorder of energy balance. When food-derived energy chronically exceeds energy expenditure, the excess calories are stored as triglycerides in adipose tissue. Notwithstanding the marked fluctuations in daily food intake, body weight remains remarkably stable in most humans. In response to alterations in body adiposity, the brain triggers compensatory physiological adaptations that resist weight change. The two sides of the energy equation, i.e., consumption and expenditure, are finely regulated by neural and humoral mechanisms [5,6]. These neural and humoral mechanisms work in concert as the neurohumoral system to maintain body energy status. The neurohumoral system is comprised of the afferent pathway, the central processing unit, and the efferent pathway [5] (Fig. 1).

The afferent system generates humoral signals from adipose tissue (leptin), pancreas (insulin), and stomach (ghrelin). Acting in the brain, leptin and, to a lesser extent, insulin decrease food intake and increase energy expenditure, promoting weight loss. They are consequently termed catabolic adiposity signals. Impinging on the same neuronal targets, ghrelin exerts opposite effects and is thus an anabolic hormone. The amount of leptin is in direct proportion to adipose stores. Weight gain evokes proportionate increases in catabolic hormones and decreases ghrelin, whereas weight loss causes the opposite [5]. Long-term regulation of energy stores depends on adiposity signals like leptin and insulin.
while ghrelin communicates short-term changes in nutritional status. Apart from ghrelin, many other gastrointestinal signals communicate short-term alterations in nutritional status to the brain via humoral and neural stimuli. A number of satiety signals that are released from the intestine include cholecystokinin (CCK), pancreatic polypeptide (PP), peptide-YY (PYY), oxyntomodulin, enterostatin, and glucagon-like peptide-1 (GLP-1) [5-10]. Another satiety signal, amylin, is cosecreted with insulin from the pancreas. These short-acting satiety and hunger signals are transmitted via afferent fibers of the vagus nerve to the caudal brainstem in nucleus tractus solitarius, from where they also influence the hypothalamus. The sensitivity of brainstem responses to afferent gastrointestinal signals is modulated by long-acting catabolic adiposity signals [5] (Fig. 2).

The central processing unit is located primarily in the hypothalamus, especially in the arcuate nucleus, which integrates the afferent signals from leptin, insulin, and ghrelin. There are two major types of neurons in this locale that bear leptin receptors; these are anorexigenic neurons and orexigenic neurons. Pro-opiomelanocortin (POMC) and cocaine-and amphetamine-related transcript (CART) neurons are first-order anorexigenic neurons. These are activated by leptin and secrete α-melanocyte stimulating hormone (α-MSH), which acts on second-order neurons present in the paraventricular area that express melanocortin 4 receptor (MC4R). The signaling through these pathways induces expression of corticotrophic-releasing hormone (CRH) and thyrotrophin-releasing hormone (TRH) [5]. Neuropeptide Y (NPY)/Agouti-related peptide (AgRP) neurons are the first-order orexigenic neurons. They produce NPY and AgRP, which are the initial targets of leptin action. NPY acts on second-order neurons in the lateral hypothalamic area and the perifornical area. The second-order neurons express orexigenic peptides that are melanin-concentrating hormone (MCH) and orexins A and B. The signaling through these neurons is increased by ghrelin and attenuated by leptin. AgRP exerts its anabolic effect by inhibiting the anorexigenic or melanocortin arm [5].

---

**Fig. (1). Neuroendocrine control of energy homeostasis (details in text).**

1: afferent system generates signals released from adipose tissue (leptin), pancreas (insulin) and stomach (ghrelin)
2: central processing unit present in hypothalamus having two sets of neurons: orexigenic and anorexigenic neurons
3: efferent system carries out anabolic and catabolic signals by modulating feeding behavior or energy expenditure

NPY/AgRP = Neuropeptide Y/Agouti related peptide; POMC/CART = Pro-opiomelanocortin/Cocaine and Amphetamine Related Transcript; NPY Rec = Neuropeptide receptor; MCH = Melanin Concentrating Hormone; αMSH = α Melanocyte Stimulating Hormone; Mc4R = Melanocortin receptor; TRH = Thyrotrophin Releasing Hormone; CRH = Corticotrophic Releasing Hormone
The efferent system carries out orders from the hypothalamic nuclei in the form of feeding behavior and energy expenditure [5]. Anorexigenic signaling through TRH and CRH induces anorexia and thermogenesis. On the other hand, the orexigenic signaling via orexigenic peptides (MCH and orexin A and B neuropeptides) results in increased food intake and decreased energy expenditure.

Several neurotransmitters (serotonin, noradrenaline, dopamine, and histamine), peptides (neuromedin U, urocortin, bombesin, amylin, galanin), hormones (thyroid hormone, growth hormone) and cytokines (ciliary neurotrophic factor) also play a role in modulating feeding behavior and energy expenditure [5-10].

**LEPTIN AND LEPTIN RESISTANCE**

Leptin is an important hormone that maintains body weight by acting through a negative feedback mechanism of energy consumption and utilization. The finding that leptin deficiency in animals results in morbid obesity generated hope that exogenous administration of leptin would ameliorate obesity [11]. However, as common obesity is a state of leptin resistance, the exogenous administration of even exceedingly high doses of leptin has proven relatively ineffective at reducing body weight [14-16].

In the past few years, insight into the mechanisms of leptin resistance has been elucidated. Leptin resistance results from impairments in leptin action at multiple levels. Leptin is usually transported across the blood-brain barrier by a specialized leptin transporter that is impaired in obesity [17]. In mice, a high-fat diet has also been shown to impair leptin signaling by attenuating STAT3 activation, thus contributing to leptin resistance [18]. Leptin receptor activation engages intracellular proteins, such as protein tyrosine phosphatase1B (PTP1B) and suppressor of cytokine signaling-3, that terminate receptor signaling. Increased activity of these autoinhibitory factors attenuates leptin signaling and is also implicated in leptin resistance [17]. All of these factors are targeted in drug development in order to increase leptin sensitivity in obese individuals (Fig. 3).
Fig. (3). Strategies to overcome leptin resistance (Details in text)
Step 1: Modified leptin bypassing normal brain transport or use of intranasal leptin
Step 2: Stimulating leptin signaling:
- Activating STAT3, an important transcription factor recruited during leptin signaling
- SOCS3 & PTP1B antagonists (inhibition of autoinhibitory factors involved in leptin signaling)
Step 3: Melanocortin Mc4 receptor agonist (downstream pathway of leptin signaling exerting anorectic and thermogenic effect)
Step 4: Stimulating melanocortin signaling: SIM1 stimulation (a transcription factor that acts as a mediator for the anorectic, but not thermogenic effects of melanocortins)
ARC= Arcuate nucleus; PVC= paraventricular nucleus; JAK= Janus kinase; STAT3= Signal transducers and activators of transcription; SOCS3= Suppressor of cytokine signaling-3; PTP1B= Protein tyrosine Phosphatase1B; α MSH= α Melanocyte stimulating hormone; Mc4R= Melanocortin receptor; TRH= Thyrotrophin Releasing Hormone ;CRH= Corticotrophic Releasing Hormone; SIM1= Single-minded homologue 1.

The history of the pharmacotherapy of obesity dates back to the 1930s. Many drugs used to treat obesity in the past have been discontinued because of their potential to be abused and their toxicities [20-27] (Table 1). Rimonabant is a cannabinoid receptor 1 antagonist that became available for long-term treatment of obesity in the United Kingdom and other countries beginning in 2006 [27]. In the United States, the FDA did not approve the agent because of its association with a risk of psychiatric disorders including depression and suicidal tendencies [27]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21]. In 2009, the EMEA (European Medicine Agency) withdrew market authorisation for rimonabant in all countries of the European Union due to safety concerns [21].

Sibutramine, a popular antiobesity drug used worldwide since 1997, was withdrawn from the European and US markets in 2010 because of safety concerns [27,28]. In the Sibutramine Cardiovascular Outcomes (SCOUT) trial, the drug was shown to be associated with increased risk of major adverse cardiovascular events (a composite of non-fatal heart attack, non-fatal stroke, resuscitation after cardiac arrest, and cardiovascular death) in obese patients, as compared to placebo [29].

The medications currently approved by the FDA for use in the United States include phendimetrazine, benzphetamine, diethylpropion, phentermine, and orlistat. The US Drug Enforcement Administration classifies phendimetrazine and benzphetamine as schedule 3 drugs and diethylpropion and phentermine as schedule 4 drugs [20,30]. These drugs are recommended for the short-term (12 weeks or less) treatment of obesity [20,30].

Orlistat is the only drug currently approved by the FDA for long-term management of obesity [21,31]. It acts by reversibly inhibiting pancreatic lipase enzyme, thus preventing the hydrolyzation and absorption of dietary fat by approximately 30%, and thereby decreasing the caloric intake of obese patients [32]. A meta-analysis of 29 studies of orlistat for weight loss in adult patients reported a weight loss of 2.59 kg and 2.89 kg at 6 months and 12 months, respectively [33,34]. In comparison to patients on diet and placebo only, the patients treated with orlistat demonstrated a significant improvement in blood glucose concentrations, insulin resistance, waist circumference, total and low-density lipoprotein cholesterol (LDL-C), and blood pressure [35-37]. Owing to the unabsorbed fat in the intestine, orlistat causes some side effects, among which the most common are diarrhea, flatulence, bloating, abdominal pain, and dyspepsia [38].
Classification of anti-obesity drugs

- Decreasing energy intake
  - Altering adipocyte differentiation from WAT to BAT: PPAR gamma co activator 1 modulation
  - Suppressing appetite
    - Stimulators of anorexigenic pathway
      - Leptin: oral/Intranasal
        - Overcoming leptin resistance: PTP1B antagonists and SOCS3 antagonists
        - Melanocortin agonists & SIM1 stimulators
        - Cannabinoid receptor1 antagonists
        - Increased mesenchymal neurotrophic factor
        - Specific SHT receptor modulators
        - Histamine 3 receptor antagonists
        - Neprilysin analogues
        - CRF receptor modulators or un coercin analogues
        - Neurenomedin U analogues
        - FAS inhibitors
        - Bombesin receptor modulators
      - Neuropeptide Y antagonists
  - Inhibitors of orexigenic pathway
    - Melanin concentrating hormone
    - Corticotrophin releasing factor
    - Glucagon Like peptide1
    - Pankreatic polypeptide
    - Fatty acid synthase
    - Melanin concentrating hormone
    - Corticotrophin releasing factor
    - Glucagon Like peptide1
    - Pankreatic polypeptide
    - Fatty acid synthase
  - Increasing energy expenditure
    - Increasing thermogenesis
      - Thyroid hormone beta subhype agonists
      - Growth hormone analogue
      - B3 adrenoceptor agonists
      - Uncoupling protein 3 stimulators
    - Modulating metabolism
      - Inhibiting triglyceride formation
        - DGAT inhibitors
        - SCD1 inhibitors
        - ACC2 inhibitors
        - 11 beta HSD1 inhibitors
      - Increasing beta oxidation
        - DGAT inhibitors
        - SCD1 inhibitors
        - ACC2 inhibitors
        - Adipocyte complement-related protein (Acrp30) or adiponectin
        - 11 beta HSD1 inhibitors

Fig. (4). Classification of antiobesity drugs according to mechanism of action (details in text)

WAT= White adipose tissue; BAT= Brown adipose tissue; PPAR= Peroxisome proliferator-activated receptors; SOCS3= Suppressor of Cytokine Signaling-3; PTP1B= Protein Tyrosine Phosphatase1B; SIM1= Single-minded homologue 1; CNTF= Ciliary neurotrophic factor; SHT= serotonin; MCH= Melanin concentrating hormone; CCK= cholecystokinin; GLP1= Glucagon Like peptide1; PP= Pancreatic polypeptide; FAS=Fatty acid synthase; CRF= Corticotrophin releasing factor; DGAT= Diacylglycerol acyltransferase; SCD= Stearoyl CoA desaturase; ACC= Acetyl coA carboxylase; HSD= Hydroxysteroid dehydrogenase.
The only currently approved long-term therapy for obesity in the United States is not only having limited efficacy, but is also associated with number of side effects. Thus, a dire need exists for the development of novel antiobesity drugs with high efficacy and long-term safety. In recent years, there has been an explosion in knowledge of the mechanisms involved in the regulation of feeding behavior and the cellular mechanisms involved in energy expenditure. This has led to a rich harvest of new potential targets and drug candidates that may offer hope of safe and effective treatments for obesity.

NOVEL TARGETS AND DRUG CANDIDATES

Drugs that Decrease Energy Intake

These include appetite suppressants and lipase inhibitors. Among the appetite suppressants, the targets are classified according to the energy pathways they modulate. These can either be stimulators of anorexigenic pathways or inhibitors of orexigenic pathways (Fig. 4). The lipase inhibitors inhibit dietary fat absorption and hence decrease energy intake.

Appetite Suppressants: Stimulators of anorexigenic pathway

Leptin. Leptin treatment has proved to be ineffective for attaining weight reduction in obese individuals. However, the use of low doses of leptin to maintain weight loss attained by other anorectic medicines and lifestyle modifications is emerging as a pharmacotherapeutic option [39,40]. In human beings, the maintenance of reduced body weight is achieved via coordination of metabolic, neuroendocrine, and autonomic responses that normally favor weight regain following a loss [40]. Weight loss decreases energy expenditure, reduces the tone of the sympathetic nervous system, and decreases the circulating levels of leptin and thyroid hormones [40]. The weight-reduced state is considered to be a state of relative leptin deficiency [41-43]. These counter-regulatory changes induce hyperphagia and a hypometabolic state, which result in tachyphylaxis to anorectic medications and favor weight regain. Administration of low doses of leptin in humans after weight loss has been shown to reverse these counter-regulatory neuroendocrine responses and increase energy expenditure, thus maintaining the weight reduction [40,44].

Leptin mimetics. To overcome leptin resistance (Fig. 3), drugs that can bypass the leptin transporter are being explored. These include oral leptin mimetics and intranasal leptin, both of which are in preclinical stages of drug development [15,45,46].

Stimulating leptin signaling. Recent preclinical evidence has shown that coadministration of amylin with leptin improves leptin-mediated STAT3 signaling in the ventromedial hypothalamus of rats with diet-induced obesity [47]. This observation suggests that combination therapy with leptin and amylin has potential for the treatment of obesity. One such combination therapy is currently being evaluated in clinical trials and is discussed later in this article.

Another strategy to improve sensitivity to leptin is to inhibit the autoinhibitory factors involved in leptin signaling, i.e., suppressor of cytokine signaling-3 and PTP1B. This strategy is particularly compelling as the activity of these autoinhibitory factors is increased in obesity, hinting at an etiological role for them in leptin resistance [15,48,49]. Suppressor of cytokine signaling-3 haploinsuffi-
ciency in mice enhances the weight-reducing effects of leptin and confers resistance to diet-induced obesity [50]. PTP1B is a negative regulator of the leptin and insulin signaling pathways, so it has emerged as an attractive novel target for the treatment of both type 2 diabetes and obesity [51]. The development of PTP1B inhibitors for the treatment of obesity is in preclinical stages. One PTP1B inhibitor, trodusquemine, has been shown to suppress appetite, reduce body weight, and improve plasma insulin and leptin levels in a murine model of diet-induced obesity [52].

Another logical strategy to overcome leptin resistance is to manipulate leptin-regulated pathways distal to the first-order neuron, which is the melanocortin pathway.

**Melanocortin pathway stimulation.** In the leptin-melanocortin pathway, POMC is the first key intermediary downstream of leptin-receptor signaling. Pharmacological mechanisms to increase POMC expression are not evident, due to the involvement of POMC-derived peptides in adrenal physiology [53]. Hence, the downstream pathways are targeted for drug development.

**Melanocortin receptor agonists.** Cleavage of POMC produces, among other peptides, α-MSH, which activates melanocortin 3 and 4 receptors (Mc3r, Mc4r) to exert catabolic effects [54]. These receptors are highly promising targets for obesity treatment because of their vital functions and relative specificity in energy homeostasis [55]. Ample genetic evidence proves Mc4r signaling to be a critical component of the body-weight regulation system. Null mutations in Mc4r cause pronounced, dominantly inherited, monogenic obesity in rodents and humans, and are associated with increased food intake, decreased energy expenditure, and increased lean body and fat mass [56, 57]. These observations have led to the development of Mc4 receptor agonists; however, their development has proceeded less successfully than expected due to the melanocortin pathway’s role in increasing heart rate and blood pressure as well as induction of penile erection [58, 59]. These effects cannot be dissociated from that of appetite. There is also ample evidence to demonstrate that stimulation of the melanocortin pathway by inflammatory cytokines results in cachexia. This is another issue of concern with long-term use of melanocortin agonists [60, 61]. Some Mc4 receptor agonists have been tested in preclinical and clinical studies. A melanocortin 4 receptor agonist, 3 RY764, reduced food intake and augmented erectile activity in rodents [62]. MK-0493, another potent and selective agonist of Mc4 receptor, was associated with statistically insignificant weight reductions in a clinical trial [63]. (Table 3) Given these discouraging results, Mc4 receptor agonists are currently not being developed for the treatment of obesity. However, they are being explored for other conditions such as sexual dysfunction [64]. Melanocortin antagonists are also being evaluated for the treatment of cachexia [65, 66].

**Melanocortin receptor signaling.** Recent evidence indicates the single-minded homologue 1 (SIM1) transcription factor acts as a proximal mediator for the anorectic, but not thermogenic, effects of melanocortins [67]. In rodents and in humans genetic evidence demonstrates that the loss of SIM1 causes hyperphagic obesity in addition to causing resistance to the anorectic effects of melanocortins [68, 69]. Conversely, SIM1 overexpression reduces food ingestion and body weight in mice fed a high-fat diet, acting downstream of melanocortin receptors [70]. These observations identify SIM1 stimulation as a potential antiobesity strategy.

**Ciliary neurotrophic factor.** Ciliary neurotrophic factor (CNTF) is a glial cell-produced neuroprotective cytokine. It has been explored for the treatment of neurodegenerative diseases. Unexpectedly, subjects receiving CNTF in clinical trials for this indication experienced weight losses of 10–15%, prompting researchers to consider using CNTF to treat obesity [71]. CNTF either cross-reacts with leptin receptors or directly activates its own receptors present on the hypothalamus, initiating a transduction pathway analogous to that of leptin [72]. In hypothalamic feeding centers, CNTF stimulates the proliferation of neurons that contain leptin-responsive elements [73]. Based on these promising findings, axokine, a recombinant human variant of CNTF, was used for testing in humans. Modestly successful results were observed in phase 1 and 2 clinical trials [74]. However, in one year-long phase 3 trial involving 2,000 severely obese patients, disappointing results were seen in the axokine-treated group [75]. In this trial, axokine resulted in an average weight loss of 2.9 kg, as compared to an average weight loss of 1.1 kg with placebo. While the difference was considered statistically significant, it fell short of the goal set by the FDA for the approval of antiobesity drugs, which is a 5% weight loss beyond that achieved with placebo. (Table 3) This limited efficacy was due to the development of anti-CNTF antibodies in these patients [75]. CNTF congeners that do not elicit an immune response would be rational antiobesity drug candidates in the future [15].

**Reuptake inhibitor of serotonin, noradrenaline, and dopamine.** Tesofensine increases monoaminergic transmission by inhibiting the neuronal uptake of serotonin, dopamine, and noradrenaline, thus causing appetite suppression. In phase 2b clinical trials, this drug achieved degrees of weight loss that were significantly greater than those achieved with any other currently available antiobesity drug [76]. Over a period of 6 months, patients lost an average of 12.8 kg, 11.3 kg, and 6.7 kg on the 1 mg, 0.5 mg, and 0.25 mg doses, respectively, as compared to a 2.2 kg weight loss in the placebo group [76]. The most common adverse effects in the tesofensine group were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia. Tesofensine also increased blood pressure, heart rate, and frequency of mood changes. Tesofensine at doses of 0.5 mg and 1.0 mg increased heart rate by 7.4 and 8.1 beats per min, respectively [76]. This effect on heart rate is an important safety issue that needs special attention in future trials since obese individuals are at increased cardiovascular risk. Another issue of concern that must be comprehensively explored in future trials is the association between tesofensine and increased frequency of agitation and mood changes. Its efficacy and tolerability is currently being evaluated in a phase 3 trial [77] (Table 2).
Table 2. Drugs in Early or Late Stage of Clinical Development

| Current Development Status | Drug             | Pharmacological Approach                        | Pharmaceutical Company                        | References |
|----------------------------|------------------|-------------------------------------------------|-----------------------------------------------|------------|
| Phase 3                    | Cetilistat       | Pancreatic lipase inhibitor                     | Amylin Pharmaceuticals Inc./Takeda Pharmaceutical Co. Ltd | Kogelman et al. (2007) [185], Kogelman et al. (2010) [186], Padwal R (2008) [187] |
|                            | Tesofensine      | Reuptake inhibitor of noradrenaline, dopamine and serotonin | NeuroSearch A/S                                | Astrup et al. (2008) [76], Bello et al. (2009) [77] |
|                            | Liraglutide      | GLP1 agonist                                    | Novo Nordisk A/S                               | Astrup et al. (2009) [127], Neary et al. (2009) [128] |
| Phase 2                    | Obinepitide      | Analogue of PYY3-36 and PP. Agonist of neuropeptide Y2 and Y4 receptor | 7TM Pharma                                     | Neary et al. (2009) [128] |
|                            | Empatic          | Combination of bupropion and zonisamide         | Orexigen Therapeutics Inc                      | Valentino et al. (2010) [192] |
| Phase 1                    | OAP 189 (TKS-1225) | Oxymontomodulin analogue            | Pfizer Inc (previously developed by Thiaakis/Wyeth) | Wyne et al. (2006) [135], Bloomgarden ZT (2009) [136], McGavigan et al. (2012) [137] |

(Abbreviations: PYY3-36: peptide YY3-36; PP= pancreatic polypeptide; GLP1: glucagon-like peptide1)

**Serotonin (5-HT) receptor modulation.** The nonselective serotoninergic antiobesity drugs fenfluramine and dexfenfluramine have been associated with severe side effects like valvular heart disease and pulmonary hypertension; as a result, these drugs were discontinued [78,79]. A detailed analysis of the antiobesity action of fenfluramine disclosed that it directly activates hypothalamic POMC neurons through 5-hydroxytryptamine 2C (5-HT2C) receptors that are expressed on a majority of these cells [80]. This finding led to selective targeting of 5-HT2C receptors in the brain. Lorcaserin is a selective agonist of the 5-HT2C serotonin receptor in the hypothalamus, which regulates satiety and the metabolic rate [81]. In a phase 2 clinical study, patients who were administered 20 mg/day lorcaserin attained an average weight loss of 3.6 kg, which was significantly greater than the average weight loss of 0.3 kg in the placebo group [82].

Two phase 3 trials BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behavioral modification and Lorcaserin Second Study for Obesity Management) evaluated obese and overweight patients to demonstrate the efficacy of lorcaserin (10 mg twice daily) over placebo [83,84]. In the BLOOM trial, patients treated with lorcaserin achieved highly significant and absolute weight loss in 1 year, and continuous treatment with lorcaserin over 2 years helped two-thirds of the patients maintain a weight loss of 5% or greater [83]. The average amount of weight lost on lorcaserin treatment was 5.8 ± 0.2 kg, compared with 2.2 ± 0.1 kg in the placebo group (P<0.001). Lorcaserin was very well tolerated; it did not result in increased risk of depression or the development of cardiac valvular insufficiency. The BLOSSOM trial confirmed the results reported by the BLOOM trial [84]. In this 52-week trial, 47.2% of patients in the lorcaserin group lost at least 5% of their body weight, compared to 25% of patients in the placebo group [84]. In the lorcaserin group, 22.6% of patients lost at least 10% of their body weight, as compared to 9.7% of patients in the placebo group [84]. Lorcaserin had successfully completed phase 3 trials and its new drug application was reviewed by the FDA [B87]C. The drug failed to get FDA approval because of safety concerns Related to the finding that high doses of the drug were associated with tumor formation in rats [85] (Table 3).

5-HT6 receptors have also been targeted for the treatment of obesity. Central application of antisense oligonucleotide against 5-HT6 receptors decreased food intake in rats [86]. Selective 5-HT6 receptor antagonists have also been shown to reduce body weight in mice with diet-induced obesity [87]. However, recent evidence suggests the distribution of 5-HT6 receptors in the mouse brain is very different from that in rats or humans [88]. As a result, the potential role of the 5-HT6 receptor in regulating human energy homeostasis requires additional evaluation.

**Histamine H3 receptor antagonists.** Histamine-synthesizing neurons in the tuberomammillary nucleus project to the paraventricular nucleus and the ventromedial hypothalamus, two hypothalamic regions recognized to regulate food intake [89]. In 2001, Masaki et al. reported that central infusion of histamine in a leptin-resistant mouse
model of obesity reduced fat accumulation, decreased leptin, and improved insulin sensitivity [90]. These findings initiated the development of H3 receptor antagonists, which increase histamine levels in the hypothalamus and decrease food intake. Novo Nordisk extensively investigated the antiobesity action of the potent and selective non-imidazole H3 receptor antagonist NNC38-1202. However, NNC38-1202 did not progress as an antiobesity pharmaceutical option due to possible drug interactions [91]. Schering plough was evaluating another H3 receptor antagonist, SCH497079, as an antiobesity drug candidate in phase 2 trial. The data of its clinical testing are not available [92].

Table 3. Drugs not Being Pursued for Future Development or for which Current Status is Not Known

| Stage of Development in which the Drug Failed or was Not Pursued Further | Drug     | Pharmacological Approach          | Pharmaceutical Company           | Comment                                                                 | Reference                           |
|---|----------------|---------------------------------|---------------------------------|--------------------------------------------------------------------------|------------------------------------|
| NDA rejected by FDA          | Lorcaserin | Selective serotonin receptor agonist | Arena Pharmaceuticals Inc        | High doses of the drug associated with tumor formation in rats          | Smith et al. (2010) [83], Fidler et al. (2011) [84], Pollack A (2010) [85] |
|                             | Qnexa      | Low doses of phentermine and topiramate | Vivus Inc                      | Rejected due to safety concerns including increased heart rate, teratogenic potential and psychiatric problems | Gadde et al. (2011) [246], Pollack A (2010) [247] |
|                              | Contrace   | Fixed dose combination of bupropion and naltrexone | Orexigen Therapeutics           | Deferred approval till cardiovascular safety concerns are addressed     | Greenway et al. (2010) [240], Wadden et al. (2011) [242], Pollack A (2011) [243] |
|                              | Axokine    | Recombinant CNTF                 | Regeneron Pharmaceuticals Inc    | Failed due to development of antibodies against CNTF                    | Ettinger et al. (2003) [74], Pollack A (2003) [75] |
| Phase 3                      | PYY3-36 (nasal) | Neuropeptide presynaptic Y2 receptor agonist | Nastech Pharmaceutical Company  | Did not meet primary efficacy endpoint                                  | Gantz et al. (2007) [131]          |
|                              | GI181771X  | CCK1 receptor agonists           | Glaxo Smithkline                | Failed to demonstrate efficacy                                          | Jordan et al. (2008) [116]         |
|                              | AOD 9604   | Growth hormone analogue          | Metabolic Pharmaceuticals Inc    | Drug failed to demonstrate efficacy in phase 2b studies                  | Valentino et al. (2010) [192]      |
|                              | MK0557     | Neuropeptide Y 5 receptor antagonist | Merck & Co., Inc.               | Failed to demonstrate efficacy                                          | Erondu et al. (2006) [155]         |
|                              | SCH497079  | Histamine 3 receptor antagonist  | Schering plough                 | Current status not known                                                 | ClinicalTrial.gov [92]             |
|                              | MK-0493    | Melanocortin 4 receptor agonist  | Merck & Co., Inc.               | Lack of efficacy                                                         | Krishna et al. (2009) [63]         |
|                              | Pramlinitide and metreleptin | Combination of long-term adiposity signal eg. leptin (metreleptin, analog of human leptin) and short-term satiety signals e.g. amylitin (pramlinitide, analog of amylitin) | Amylin Pharmaceuticals Inc, Takeda Pharmaceuticals Limited | Discontinued the project after commercial reassessment                     | Ravussin et al. (2009) [248], Tam et al. (2011) [249] |
**Hoodia gordonii extract.** The *Hoodia gordonii* cactus plant was traditionally used by the Bushmen of the Kalahari Desert to suppress hunger. The South Africa’s Council for Scientific and Industrial Research (CSIR) investigated the appetite suppressant activity of *Hoodia* extracts and made a breakthrough with structure elucidation of an active ingredient, p57 [94]. In 1998, CSIR licensed an agreement with Phytopharm (a British pharmaceutical company specializing in Phytomedicines) to further develop p57 [94]. Phytopharm collaborated with Pfizer for development and commercialization of the extract. In an early clinical trial of 19 obese subjects, either p57 or placebo was administered for 15 days. A statistically significant reduction was observed in the average daily calorie intake in the p57 group compared with the placebo group, and no serious adverse effects were experienced by any of the subjects [94,95]. However, in 2003, Pfizer ended its collaboration with Phytopharm citing difficulties in synthesizing the extract in drug form [94,96] (Table 3). In 2004, Unilever entered into an agreement with Phytopharm to start marketing *Hoodia gordonii* commercially in the form of a functional food for obesity management [94]. However, in 2008, Unilever severed its agreement with Phytopharm as the extract could not live to their expectations of safety and efficacy [94]. (Table 3) Much work remains to be done before the scientific evidence supports the use of Hoodia plant extract as an appetite suppressant.

**Nesfatin.** Nesfatin-1/nucleobindin 2 (NuCB2) is a naturally occurring satiety molecule produced in the brains of mammals [97]. Chronic intracerebroventricular injection of nesfatin-1 in rats has been shown to reduce body weight, whereas that of antisense oligonucleotide against the NuCB2-encoding gene increased body weight [98]. These findings suggest nesfatin and its analogues have potential as possible antiobesity drug candidates.

**Corticotrophin releasing factor (CRF)/urocortin.** The CRF-like neuropeptide (urocortin), acting via CRF2 receptors in the brain, is a potent suppressor of appetite [99]. Administration of urocortin-3 in the ventromedial hypothalamus suppresses feeding and elevates blood glucose levels in rats, suggesting the activation of CRF2 receptor in the brain promotes stress-like responses [100]. It was recently shown that transgenic mice overexpressing urocortin-3 were protected against the untoward metabolic consequences of an obesogenic high-fat diet challenge [101]. These observations indicate urocortin may be another antiobesity drug target with promise.

**Neuromedin U.** Neuromedin U (or NmU) is a neuropeptide found in the brains of humans and other mammals. This peptide is involved in diverse physiological functions, including appetite suppression [102]. Intracerebroventricular administration of neuromedin U in rats is associated with marked reductions in body weight [103]. On the other hand, injection of an antibody to neuromedin U increased food ingestion [103]. In mice with diet-induced obesity, intracerebroventricular infusion of NmU for 7 days decreased body weight and total energy intake as compared with the mice given intracerebroventricular infusion of vehicle [104]. The role of neuromedin U as an appetite suppressant acting through NmU receptor 2 (NmU2) has recently been identified from the studies using NmU2–/- mice (carrying 2 copies of the mutant NmU2 allele) [104,105]. These mice were resistant to central NmU-induced weight loss when fed a high fat diet as compared to wild type mice [105].

**Fatty acid synthase (FAS) inhibitor.** FAS enzyme is involved in the conversion of malonyl CoA to palmitate. Inhibition of FAS by a specific FAS inhibitor, C75, has been shown to reduce food intake and body weight in mice [106]. This anorectic effect is presumably mediated via interference with the expression of orexigenic neuropeptides in the brain. FAS inhibitors also stimulate carnitine palmitoyl transferase 1 (CPT-1), the rate-limiting enzyme for mitochondrial fatty acid oxidation [107]. Thus, FAS inhibitors also show potential as antiobesity agents.

**Bombesin and bombesin-like peptides.** Bombesin (and its family of bombesin-like peptides) modulates various biological and behavioral functions in humans. Intensive psychopharmacological studies in animals and humans have shown it to be an appetite suppressant [108]. Lieverse et al. demonstrated that intravenous infusion of bombesin reduced the intake of a carbohydrate-rich meal in human subjects [109-111]. However, the satiety inducing effects of bombesin were observed in lean subjects, and not in obese individuals [111].

| Stage of Development in which the Drug Failed or was Not Pursued Further | Drug | Pharmacological Approach | Pharmaceutical Company | Comment | Reference |
|---|---|---|---|---|---|
| **Hoodia P57 extract** | Appetite suppression | Phytopharm, Pfizer Inc., Unilever | Difficulty in synthesizing the extract in drug form, Inconclusive data on efficacy and safety | Vermaak et al. (2011) [94], Bray et al. (2007) [95] |
| Famoxin | Proteolytic cleavage product of adipocyte complement-related protein (Acrp30) | Genet Corporation (acquired by Serono Co. in 2003) | Current status not known | Cheetham et al. (2004) [220] |
| N-5984 | β1 adrenergic agonist | Nisshin Kyorin Pharmaceuticals Co. | Current status not known | Farrigan et al. (2002) [202] |

(Abbreviations: NDA: new drug application; FDA: Food and Drug Administration; CCK= cholecystokinin; PYY3-36: peptide YY3-36; CNTF: ciliary neurotrophic factor)
BRS-3 (bombesin receptor subtype 3) ligands comprise a new class of potential antiobesity agents that may strongly suppress feeding [112]. In animal studies, the selective antagonist of BRS3 increased food intake and body weight, whereas the selective BRS3 agonists increased metabolic rate and reduced food intake and body weight. Prolonged high levels of receptor occupancy by BRS3 agonists continued to cause weight loss in animal studies, suggesting a lack of tachyphylaxis [113].

Gastrointestinal peptides. In response to ingested nutrients, a number of peptides are released from the gastrointestinal tract. These include cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), pancreatic polypeptide (PP), oxyntomodulin, amylin, and enterostatin. These peptides act in concert with other postprandial gastrointestinal signals (e.g., gastric distention) to cause satiation and promote meal termination [7-10]. Thus, stimulation of each is being researched to determine their potential as antiobesity targets.

Cholecystokinin receptor agonists. CCK decreases food intake in numerous species including humans. It has been proposed to act as a satiety signal via CCK1 receptor activation [114]. A few non-peptide, selective CCK1 receptor agonists (GI-181771X [GlaxoSmithKline], CE326597 [Pfizer]) had been evaluated in clinical trials for obesity [115]. However, none of these compounds are currently undergoing clinical development. GI181771X, when given to obese patients for 24 weeks, failed to produce any reduction in body weight or waist circumference or to alter cardiometabolic risk markers [116]. (Table 3) A possible explanation for the failure of CCK1 agonist monotherapy might be the development of tachyphylaxis upon chronic stimulation of the receptor [117]. Though CCK monotherapy has not proven successful, some studies have reported an enhanced effect of leptin on weight reduction when it is co-administered with CCK in rats [118]. Future studies should focus on co-administration of CCK1 receptor agonists along with leptin or other hormones for the treatment of human obesity [9].

Glucagon-like peptide 1. The protease-resistant GLP-1 (glucagon-like peptide 1) congener, exenatide, is already marketed for the treatment of diabetes. In clinical trials, exenatide has been shown to reduce hemoglobin A1C, while also inducing modest but progressive weight loss that persists for at least 2 years [119]. Exenatide given subcutaneously twice daily at doses of 5 or 10 µg elicited mean weight reductions of up to 2.8 kg at 30 weeks and 5.3 kg at 3.5 years [120-122]. Exenatide administered at doses of 0.8 mg or 2 mg once weekly resulted in mean weight reductions of up to 3.8 kg at 15 weeks and 3.7 kg at 30 weeks [123,124]. Liraglutide is a novel GLP1 agonist that was approved by the FDA in January 2010 for the treatment of type 2 diabetes [125]. It has a long duration of action, is suitable for once-daily dosing and is more homologous to native GLP1 than exenatide [126]. Liraglutide has also shown promising results in clinical trials for the treatment of obesity in individuals without diabetes, resulting in weight losses of 4.8–7.2 kg with different doses ranging from 1.2 to 3 mg [127]. This was significantly higher than that seen with placebo (P = 0.003 for 1.2 mg liraglutide and P < 0.0001 for 1.8–3 mg liraglutide) and orlistat (P = 0.003 for 2.4 mg liraglutide and P < 0.0001 for 3 mg liraglutide). More than 50% of the patients on liraglutide therapy achieved a weight reduction in the range of 5–10% [127]. Nausea and vomiting were the most common side effects. These were transient in nature and rarely led to the discontinuation of therapy. Liraglutide has progressed to phase 3 trials for the treatment of obesity [128] (Table 2).

Peptide YY3-36 and pancreatic polypeptide. Peripheral administration of peptide YY 3-36 (PYY3-36) inhibits food ingestion and reduces body weight in rodents, apparently by activating autoinhibitory Y2 receptors on orexigenic NPY/Agp neurons in the hypothalamus, thereby derepressing adjacent anorexigenic POMC neurons [129]. In obese individuals, PYY3-36 intravenous infusion has been reported to ease hunger, decrease single-meal food intake by 30%, and significantly reduce the cumulative 24-hour caloric intake [130]. This treatment was well tolerated, with no complaints of altered food palatability or nausea. Based on these promising results, an intranasal formulation of PYY3-36 was evaluated in clinical trials [131]. However, this formulation demonstrated disappointing results; the amounts of weight lost at low doses were similar to those lost with placebo. Weight loss at high doses of intranasal PYY could not be assessed because 60% of patients dropped out due to nausea and vomiting. This high incidence of nausea with intranasal administration might be related to PYY’s C-max (peak serum concentration of drug), since concentration spikes with the nasal route of delivery [132]. Novel formulations providing sustained levels of PYY might be well tolerated and are desirable targets for future research.

PP is another gut-derived peptide with similar action to PYY. Obinutuzide, a synthetic analogue of both PYY3-36 and PP and an agonist of Y2 and Y4 receptors, is under clinical development [128]. (Table 2) In obese human subjects, once-daily subcutaneous dosing of obinutuzide significantly inhibited food intake up to 9 hours after dosing [128].

Oxyntomodulin. Oxyntomodulin is a product of the proglucagon gene from which GLP-1 is cleaved. In humans, intravenous infusions of oxyntomodulin have been shown to acutely lessen hunger and single-meal food intake without reducing food palatability [133]. Repeated subcutaneous injections of oxyntomodulin for 4 weeks reduced body weight by up to 2.3 ± 0.4 kg as compared with 0.5 ± 0.5 kg in the control group (P = 0.0106) [134]. Importantly, oxyntomodulin reduced single-meal intake by 25% at the start of this study and by up to 35% at the end, indicating there was no tachyphylaxis related to its anorectic effects [134]. In another study, subcutaneous injection of oxyntomodulin for 4 days reduced energy intake by 17.3 ± 5.5%, with no change in meal palatability [135]. Oxyntomodulin did not alter resting energy expenditure, but it increased activity-related energy expenditure by 26.2 ± 9.9% and total energy expenditure by 9.4 ± 4.8%. Reductions in body weight of 0.5 ± 0.2% were also observed during the period of oxyntomodulin administration. These modest and favorable results led to the development of the potent and synthetic long-acting oxyntomodulin analogue, OAP189 (TKS1225), which is currently being investigated in a phase 1 clinical trial [136,137] (Table 2).
**Amylin.** Amylin is a peptide that is postprandially cosecreted with insulin from pancreatic cells. Food intake causes a rapid increase in plasma amylin that is directly proportional to the meal size [138,139]. Amylin functions as a satiety signal by acting on area proemina in the hindbrain [140]. Administration of exogenous amylin prior to a meal dose-dependently decreases meal size in rodents thereby reduces food intake [141,142]. Amylin also suppresses gastric emptying, gastric acid output, and glucagon secretion. Pramlintide, a synthetic amylin analog, is currently marketed for the treatment of diabetes, but it has also been found to induce mild progressive weight loss in humans for at least 16 weeks [143]. In one study, subjects completing treatment with pramlintide experienced placebo-corrected reductions in body weight of 3.7 ± 0.5% [144]. Approximately 31% of the pramlintide-treated subjects achieved a weight loss of 5% or greater, as compared with 2% in the placebo group [144]. To date, much of the research with amylin has focused on its potential to increase leptin sensitivity. Infusions of an ineffective dose of leptin (500 µg/kg/day had no significant effect on the body weight of rodents with diet-induced obesity) in combination with a moderately effective dose of amylin (100 g/kg/day achieved weight losses of up to 6.5%) have been shown to elicit marked, synergistic weight loss (up to 12%) in rats with diet-induced obesity [47]. These findings provide a rationale for using pramlintide in combination with leptin for the treatment of obesity. This combination is currently being evaluated in clinical trials and is discussed again later in this article.

**Enterostatin.** Enterostatins are pentapeptides generated in the small intestine as a result of N-terminal proteolytic processing of pancreatic procolipase. Enterostatin is absorbed from the gut and acts as a powerful anorectic peptide, particularly in regards to reducing the intake of fatty foods [145]. In a study performed in rats, chronic intracerebroventricular injections of enterostatin decreased intake of a high-fat diet and reduced body weight [146]. Previous experiments explored the hypothesis that an association exists between human obesity and enterostatin dysregulation [147,148]. However, in clinical trials, intravenous enterostatin failed to show any effect on feelings of hunger, satiety, or food preference [149]. Present knowledge suggests the molecular identification of enterostatin receptors is required in order for enterostatin to be developed further as an antiobesity drug target.

**Appetite Suppressants: Inhibitors of Orexigenic Pathway**

**Neuropeptide Y receptor antagonists.** Neuropeptide Y (NPY) is a 36 amino-acid peptide that was found to potently stimulate food intake in a variety of species [10]. This led to a surge of interest in developing NPY receptor antagonists as antiobesity drugs. The orexigenic effects of NPY are chiefly mediated by the Y1 and Y5 receptors. Thus, antagonists for these receptors were viewed as potential antiobesity drugs. Neuropeptide Y1 antagonists demonstrated promising weight-reducing results in animal studies, whereas neuropeptide Y5 antagonists showed equivocal effects [150-154]. Few of these antagonists progressed to clinical trials, and since they did not live up to expectations, none are being currently pursued. NGD 951, a NPY1 antagonist, was evaluated in a phase 1b clinical trial conducted by Neurogen and Pfizer, but it was not developed further because of elevated liver enzymes [10]. MK-0557, an orally active NPY5 receptor antagonist, was evaluated in a year-long clinical trial, but since it did not produce clinically meaningful weight loss, further development was abandoned [155] (Table 3).

In addition to the disappointing clinical experience with NPY antagonists, the critical role of NPY in energy regulation was also disputed by the finding that NPY deficiency did not result in leanness in mice [15,156]. However, NPY deficiency in ob/ob (leptin deficient) mice was found to attenuate the obesity phenotype by reducing food intake and increasing energy expenditure [157]. This observation implies that NPY is required for a full response of leptin deficiency, even though it might not be required to maintain body weight. Thus, its blockade might be useful for preventing the regain of weight lost by other means [15]. More recently, interest has focused on the stimulation of presynaptic NPY2 receptors in the arcuate nucleus as a mechanism to reduce NPY release and, thus, food intake [131]. As discussed above, peptide YY (PYY), a gut hormone peptide with selectivity for NPY2 receptors, has been explored in clinical trials.

**Melanin concentrating hormone 1 receptor antagonist.** Melanin-concentrating hormone (MCH) is a 19-amino acid, cyclic neuropeptide that is present in the hypothalamus. MCH administration or its transgenic overexpression in mice increases body weight by stimulating food ingestion and adipogenesis, while decreasing energy expenditure [158,159]. This suggests that MCH1 receptor antagonists might promote weight loss, but there are several issues of concern with the development of these compounds. MCH1 receptor knockout mice demonstrate weight reduction, hyperactivity, and increased energy expenditure, but they are also hyperphagic [160]. This situation of chronically elevated energy intake due to marked hyperactivity and energy expenditure might be hazardous, as ample evidence suggests that long-term caloric restriction increases lifespan, and chronic increased calorie intake in the face of increased energy expenditure can theoretically shorten life span [161-163]. MCH antagonism also poses a risk of cardiac arrhythmias, and MCH is known to modulate many functions beyond feeding, such as locomotor activity, anxiety, aggression, sensory processing, learning, and sleep cycle [159,164,165]. Thus, it might be challenging to design anti-MCH agents that selectively regulate energy homeostasis without exerting adverse side effects. Early clinical testing of the MCH1 receptor antagonist NGD-4715 failed after recipients complained of vivid dreams and awakenings [166].

**Orexin antagonists.** Orexin A and orexin B (or hypocretin-1 and -2) are a pair of excitatory neuropeptides present in the brain. These peptides have diverse physiological functions like the regulation of feeding, the sleep-wake cycle, and the reward pathway [167,168]. It has been reported that intracerebroventricular injection of orexin increases food intake in rats [10,167,168]. The antiobesity activity of a prototype selective orexin-1 receptor antagonist, SB-334867-A, has been explored in preclinical studies [169]. This drug reduced cumulative food intake and body weight in genetically obese mice when administered over a period of 14 days [169]. Stimulation of thermogenesis also occurred, as evidenced by
an increase in uncoupling protein-1 mRNA expression in intrascapular brown adipose tissue. A single dose of SB-334867-A was found to increase metabolic rate over a period of 4 h in ob/ob mice [170].

**Galanin antagonists.** Galanin, a 29-30 amino acid neuropeptide, is widely distributed in both the central and peripheral nervous systems. Pharmacological studies indicate galanin plays a role in regulating feeding and nutritional balance [10,171]. Injection of galanin into the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus in rats significantly increases food intake [172]. Central injection of galanin stimulates the intake of fatty foods in particular [173]. Similarly, galanin gene knock-out mice also demonstrate significantly lower intake of fat in comparison with wild-type mice [174]. However, repeated galanin infusions in the third ventricle in rats failed to induce obesity or hyperphagia, suggesting tachyphylaxis may have developed [175]. Thus, further evaluation of the role of galanin in modulating feeding behavior is required. To date, three galanin receptors have been cloned and attempts are underway to synthesize specific galanin antagonists for the treatment of obesity [10,176].

**Ghrelin antagonist.** Ghrelin is an orexigenic hormone secreted from the stomach and upper intestine. Its plasma levels rise before the start of a meal (coincident with meal times of a fixed feeding schedule) and fall again rapidly after the meal is initiated [177]. This pattern of secretion implies that ghrelin plays a role in mealtime hunger and meal initiation and has led to the development of ghrelin antagonists for the treatment of obesity. However, the role of ghrelin antagonism in this aspect has been challenged by studies performed with ghrelin-deficient mice. Mice with congenital deletions of the gene encoding ghrelin or its receptor exhibited minimal body weight reductions on standard chow but they were resistant to high-fat-diet-induced obesity [178,179]. In spite of these observations, a number of other studies demonstrated that ghrelin antagonism in adult animals reduces body weight [180,181]. Ghrelin receptor antagonists have been found to decrease energy intake in lean mice, obese (ob/ob) mice, and mice with diet-induced obesity [182]. They also reduce the rate of gastric emptying. Repeated administration of ghrelin receptor antagonist has been shown to decrease body weight gain and improve glycemic control in ob/ob obese mice [183]. The possible efficacy of ghrelin inhibitors as weight-loss agents is consequently being reevaluated. Evidence is also emerging that suggests there are chronic effects of ghrelin on fat accumulation by modulation of hypothalamic genes coding for the peptides and receptors involved in energy balance regulation, independent of food intake [184].

**Lipase Inhibitors**

Lipase inhibitors inhibit gastric and pancreatic lipases in the lumen of the alimentary tract to decrease systemic absorption of dietary fat, without affecting food intake. The lipase inhibitor presently in clinical development for the treatment of obesity is cetilistat [185] (Table 2). The clinical data currently available suggest that cetilistat has comparable efficacy to orlistat (Phase 2b clinical trial showed 3 kg weight loss over placebo in 3 months). Also, as compared to orlistat, this drug has a favorable side-effect profile (90% fewer severe gastrointestinal side effects) [186,187].

**DRUGS THAT INCREASE ENERGY EXPENDITURE AND INCREASE METABOLIC ACTIVITY, THERMOGENESIS, AND LIPOLYSIS PERIPHERALLY**

**Thyroid Hormone Receptor Agonist**

Thyroid hormones are known to stimulate weight loss by increasing the metabolic rate. However, their use has been associated with cardiac stimulation and protein loss. Recently, several subtypes of the thyroid receptors have been discovered. The alpha subtype is located in the heart and mediates the cardiotimulatory effect of the thyroid hormones. The beta subtype is chiefly located in the liver and is involved in hepatic cholesterol metabolism. A beta subtype-specific agonist, KB-141, has been developed [188]. In one study, KB-141 was administered orally to obese Zucker fa/fa rats for 21 days and.ob/ob mice for 7 days, after which body weight, adiposity, and lipid levels were examined [189]. In fa/fa rats, KB-141 reduced body weight by 6–8% and adiposity by 5–6%, without causing tachycardia. In ob/ob mice, KB-141 lowered serum cholesterol, triacylglycerols, and both serum and hepatic levels of free fatty acids, without causing tachycardia. Treatment of ob/ob mice with KB-141 for 2 weeks improved glucose tolerance and insulin sensitivity in a dose-dependent manner with no effect on heart rate [189]. Another thyroid beta subtype receptor agonist, GC1, when administered to cynomolgus monkeys for 7 days, caused significant reductions in cholesterol and lipoprotein (a), and an average weight loss of 4%, without causing cardiac stimulation [190].

**Human Growth Hormone Analogue**

Growth hormone has profound lipolytic and antilipogenic activity and is known to reduce body fat and cause weight loss. AOD-9604 is an orally active analogue of peptide fragment of human growth hormone (hGH 177–191) that selectively activates lipolysis in adipose tissue. In one study, AOD-9604 reduced body weight in genetically obese Zucker rats and ob/ob mice, without inducing the untoward effect on glycemic control normally observed with growth hormone [191]. In a 12-week randomized clinical trial, subjects receiving AOD-9604 (1 mg/d) lost an average of 2.6 kg, compared to 0.8 kg in the placebo group [192]. Development of this drug was terminated in 2007 as the drug failed to induce significant weight loss in a 24-week trial of 536 subjects [192] (Table 3).

**β3-adrenoceptor Agonists**

β3-adrenoceptor agonists were first described as an antiobesity target in 1983, and their seven-transmembrane G-protein-coupled β3-adrenoceptor was cloned 6 years later [193,194]. To date, however, β3-adrenoceptor agonists have not been marketed for the treatment of obesity. The first generation β3-agonists were selected on the basis of their thermogenic and antiobesity actions observed in rats and mice. In obese rodents, they produced good weight loss results by increasing metabolic rate. Unfortunately, clinical experience with these compounds has been less encouraging.
The side effects of first-generation compounds in humans were tachycardia and tremors, indicating lack of $\beta_3$ receptor selectivity. They were also not effective at reducing weight by increasing thermogenesis, since their agonistic potential for human $\beta_3$ receptors was not as strong as for rodent $\beta_3$-adrenoceptors [10,195,196]. In rodents, the $\beta_3$-receptors are present in both white adipose tissue and brown adipose tissue (BAT), but in humans, $\beta_3$ receptors are predominantly present in BAT. Newborn infants have relatively large amounts of BAT, which plays a thermoregulatory role in affording protection from cold exposure. However, with increasing age, the amount of BAT decreases. Thus, it has been argued that the expression of $\beta_3$ receptors might be insufficient in human adults for $\beta_3$-adrenoceptor agonists to elicit a response [10,195]. Treatment of obese patients with the first-generation $\beta_3$ agonists BRL26830 and BRL35135 had no effect on thermogenesis or fuel metabolism. These drugs also caused undesirable tremors and tachycardia [195, 197, 198].

The presence of BAT and its physiological role in adults has been a subject of great debate. Recently, the presence of BAT in adult humans was demonstrated with radiological evidence [199]. In addition, body mass index and the amount of BAT have been shown to be inversely proportional, especially in older patients; this suggests BAT may play a protective role against obesity in adults [199]. A few studies have also shown that chronic stimulation with selective agonists causes upregulation of $\beta_3$-adrenoceptors and induces BAT hypertrophy in rodents, dogs, and monkeys, a finding that suggests recruitment of BAT could also occur in humans. These recent developments have led to a resurgence of research into drugs targeting $\beta_3$ receptors. Novel generation of highly selective $\beta_3$ receptor agonists have been tried in clinical trials [10, 19, 200, 201]. CL 316243 increased insulin-mediated glucose disposal and fat oxidation in human volunteers, without causing tremors and cardiac stimulation [200]. However, the poor oral bioavailability of CL316243 is a major drawback. Prodrugs with improved bioavailability have also been developed [201]. The oral bioavailability of a single dose of LY377604 was greater than 20%, and in obese subjects it was shown to increase metabolic rate by 17.5% [10]. Another $\beta_3$ agonist N5984, developed by Nisshin Kyo- rin Pharmaceuticals was in early phase of clinical testing. However, the clinical study data for N5984 is not available [202] (Table 3).

**Uncoupling Proteins**

Uncoupling protein 1 (UCP1) or thermogenin, a member of the mitochondrial transporter superfamily, is involved in energy expenditure and brown fat thermogenesis. UCP1 protein dissociates the mitochondrial fatty acid oxidation from production of ATP and the energy is dissipated as heat (Fig. 5) [10, 203]. This is a key process for non-shivering thermogenesis and body weight regulation in mammals [203]. Although UCP1 is very well characterized, it has not been pursued as a target for increasing energy expenditure be-

![Fig. (5). Mechanism of uncoupling proteins.]()

UCP= Uncoupling protein
UCP1: Unique to brown fat
UCP2: Widely distributed in the body
UCP3: Mainly in skeletal muscle
Stimulation of UCP3 might have beneficial effects for obesity management
ETS= Electron transport chain; ADP= Adenosine diphosphate; ATP= Adenosine-5’-triphosphate; NADPH= Nicotinamide adenine dinucleotide phosphate H⁺
cause the protein is uniquely present in BAT, which is barely detected in adult humans. In the past few years, a few proteins with high sequence homology to UCP1 have been discovered that are also expressed in non-BAT. These include UCP2, which is widely distributed in the body, and UCP3, which is expressed mainly in skeletal muscle [204]. Owing to the ubiquitous localization of UCP2, the likelihood of unwanted side effects makes this protein a less appealing target for obesity treatment. In contrast, stimulation of the skeletal-muscle-specific UCP3 activity could provide a more dependable mechanism by which whole-body thermogenesis in humans could be increased. Mutations in the gene encoding UCP3 have been discovered in some individuals suffering from severe obesity and non-insulin-dependent diabetes mellitus [205]. Transgenic mice with muscle-directed overexpression of UCP3 were hyperphagic and lean when fed a palatable diet, and their glucose tolerance was improved [206]. Thus, the pharmacological stimulation of UCP3 activity could result in beneficial effects against obesity and type 2 diabetes mellitus [206].

Diacylglycerol Acyltransferase Inhibitors

Diacylglycerol acyltransferase (DGAT) enzyme catalyzes the final reaction of triacylglycerol synthesis. Two isozymes of DGAT, DGAT1 and DGAT2, have been described. DGAT1 plays an important role in the synthesis of very-low-density lipoprotein (VLDL). Since increased plasma VLDL concentrations might promote obesity, the inhibition of DGAT1enzyme is considered a possible therapeutic target for obesity treatment [207]. DGAT gene knockout mice are resistant to diet-induced obesity and appear to compensate for the reduced ability to store fat by increasing energy expenditure [208]. A potent and highly selective DGAT1 inhibitor, compound 4a, reportedly reduced weight and liver triglycerides when dosed chronically in diet-induced obese mice [209]. It also depleted serum triglycerides in a dose-dependent manner following a lipid challenge in a murine model of obesity, thus reproducing major phenotypical characteristics of DGAT1 knockout mice [209].

Stearoyl-CoA Desaturase Inhibitors

Stearoyl-CoA desaturase (SCD) is the rate-limiting enzyme involved in monounsaturated fatty acid synthesis. It has recently been reported to be a vital control point regulating hepatic lipogenesis and lipid oxidation. SCD1-deficient mice exhibit increased energy expenditure, reduced body adiposity, and increased insulin sensitivity. These mice are resistant to diet-induced obesity [210]. Much evidence suggests that the direct antiobesity effect of SCD1 deficiency results from increased fatty acid oxidation and decreased lipid synthesis. All of these findings suggest that the pharmacological manipulation of SCD activity might be of benefit in the treatment of obesity, diabetes, and metabolic syndrome [211].

Acetyl-CoA Carboxylase Inhibitors

The acetyl-coenzyme A carboxylase (ACC) enzyme plays an important role in fatty acid metabolism in most living organisms. ACC is a biotin-dependent enzyme that catalyzes the carboxylation of acetyl-CoA to produce malonyl-CoA. Mice lacking ACC2 have continuous fatty acid oxidation and reduced body fat and body weight. This validates efforts to develop an anti-obesity drug based on antagonism of this enzyme [212].

Adipocyte-complement-related Protein or Adiponectin

Adiponectin (adipocyte-complement-related protein of 30 kDa) is a hormone produced by fat cells that is associated with fatty acid oxidation, increased insulin sensitivity, and antiatherogenic properties [213]. Adiponectin levels are inversely correlated with obesity and obesity-associated complications such as type 2 diabetes mellitus, cardiovascular disease, and hepatic dysfunction [213-216]. The association of low adiponectin levels with obesity underscores its important role in obesity-related comorbidities. It has been recognized as a key molecule in obesity as well as in the metabolic syndrome, and is a potentially promising target for the prevention and treatment of the metabolic syndrome [213, 217,218]. Famoxin is a proteolytic cleavage product of this protein. Administration of famoxin to mice has been shown to increase fatty-acid oxidation and induce weight-loss without affecting food ingestion [219]. The Genset Corporation was preparing famoxin for phase 1 clinical studies; however, further clinical development of this compound is not known when Genset was acquired by Serono Company in 2003 [220] (Table 3). A few drugs have been reported to stimulate the secretion or to induce the expression of adiponectin, including pioglitazone, endocannabinoid (CB1) receptor antagonists, and inhibitors of the renin-angiotensin pathway [221-223].

11 Beta Hydroxysteroid Dehydrogenase Type 1 Inhibitors

There is strong evidence from rodent obesity models indicating that the glucocorticoid action underlies the pathology of metabolic syndrome. In these models, it was observed that removing glucocorticoids reverses obesity and its metabolic abnormalities [224,225]. 11 beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that regenerates the active glucocorticoid cortisol from its inactive metabolite cortisone. Animals with 11β-HSD1 knockout have normal plasma glucocorticoid levels, but they cannot regenerate glucocorticoid inside liver and adipose tissue. As a result, they are protected from insulin resistance, hyperglycemia, and weight gain induced by high-fat feeding [225]. Conversely, mice with selective overexpression of 11β-HSD1 in adipose tissue have increased intra-adipose glucocorticoid concentrations, despite no change in plasma levels. These animals display a dramatic phenotype of central obesity, insulin resistance, and hyperglycemia [225]. In idiopathic obesity in humans, 11β-HSD1 activity in adipose tissue is selectively increased to a similar degree as that seen in transgenic 11β-HSD1 overexpressing mice [226]. Pharmacological inhibition of 11β-HSD1 to lower intracellular cortisol concentrations in liver and adipose tissue, without altering circulating cortisol concentrations or responses to stress, is an exciting potential therapy for obesity and diabetes. A few 11β-HSD1 inhibitors have been tested in preclinical studies. BVT.2733, an11β-HSD1inhibitor, has been reported to reduce food in-
take and weight as well as improve glucose tolerance in a mouse model of obesity and diabetes [227].

MODULATION OF FAT STORAGE OR ALTERATION OF ADIPOCYTE DIFFERENTIATION

 Peroxisome proliferator-activated receptor gamma (PPAR-γ) ligands have been reported to stimulate UCP1 expression in BAT but not in white adipocytes. This finding led to the identification of BAT-specific transcription cofactor, PPAR-γ coactivator-1 (PGC-1)[8, 228, 229]. PGC-1 is a family of transcription coactivators that functionally interact with nuclear receptor PPAR-γ [230]. It plays a cardinal role in the transcriptional programme of adaptive thermogenesis occurring in BAT as mitochondrial biogenesis, respiration, and thermogenesis [230]. Ectopic expression of PGC-1 in white adipocytes converts them to a more BAT-like phenotype [8]. The treatment of obese mice with rosiglitazone has been shown to boost PGC-1 transcription in white adipose tissue, concomitant with increased mitochondrial function and insulin sensitivity [231]. Increasing PGC-1 levels in skeletal muscle and white adipose tissue could, therefore, be potentially beneficial for the treatment of obesity and type 2 diabetes.

MIMICKING CALORIC RESTRICTION

 Caloric restriction triggers an adaptive drop in metabolic rate in rodents, nonhuman primates, and humans. This adaptation plays a central role in the rebound of body weight after weight loss observed in most patients. B19]; it also evokes beneficial effects in lowering the incidence of metabolic disorders related with aging, overweight or obesity, insulin resistance, and cardiovascular disease [19]. Caloric restriction has been demonstrated to increase lifespan in organisms, ranging from yeast to rodents, as well as in nonhuman primates [161-163,232,233]. Recently, a class of proteins known as SIRTs or sirtuins (also known as silent information regulator 2 [Sir2]-related enzymes) has been implicated in an effect of CR on lifespan extension and the prevention of comorbidities associated with obesity [233, 234]. Sirtuins are a family of enzymes with nicotinamide adenine dinucleotide-(NAD) dependent histone deacetylase or ADP-ribosyl transferase activity [235, 236]. The mammalian sirtuins (Sir1–Sir7) participate in a number of cellular and physiological functions such as gene silencing, apoptosis, mitochondrial function, energy homeostasis, and longevity [237]. Transgenic mice with overexpression of the sir1 gene demonstrate decreased lipid-induced inflammation, improved glucose tolerance, and protection from hepatic steatosis when fed a high-fat diet [238].

COMBINATION THERAPIES

 Various fixed-dose combination antiobesity drugs are in different phases of clinical development. These include the following:

Bupropion and Naltrexone (Contrace)

 Contrace is a fixed dose combination of bupropion and naltrexone in a single tablet. Bupropion, a nonselective dopamine- and norepinephrine-reuptake inhibitor, is considered to reduce weight by stimulating hypothalamic POMC neurons. The stimulation of hypothalamic POMC neurons is inhibited by β-endorphin as an opioid reward process is involved in the short-term control of eating [239]. In combination with bupropion, naltrexone, a μ-opioid receptor antagonist, acts in a synergistic manner to stimulate weight loss by blocking the β-endorphin-mediated inhibition of the POMC neuron [192]. In phase 3 trials, after 56 weeks of treatment, 62% of patients receiving contrave 32 (bupropion SR 360 mg/naltrexone SR 32 mg) lost at least 5% of their body weight as compared to 23% of patients in the placebo group [240]. Approximately 34% patients lost 10% or more of their body weight and 17% patients lost at least 15% of their mean body weight in the contrave group. Patients receiving contrave32 had a mean weight loss of 8 kg, as compared to 1.8 kg in the placebo group, after 56 weeks of treatment [240]. Obese patients on contrave also demonstrated significant improvements in important markers of cardiometabolic risk, including waist circumference, high-density lipoprotein cholesterol, insulin resistance and triglycerides. Contrace had completed phase 3 trials successfully [240-242]. Its NDA has recently been reviewed by the FDA. The FDA panel has deferred the approval of the drug, pending the conduction of a long-term study demonstrating cardiovascular safety [243] (Table 3).

Bupropion and Zonisamide (Empatic)

 Empatic is a fixed-dose combination drug containing bupropion and zonisamide. Zonisamide is an antiepileptic drug that has serotonergic and dopaminergic activity in addition to its ability to act as a blockade of sodium and calcium channels. Weight loss was an adverse effect associated with zonisamide treatment in clinical trials for epilepsy. Although the exact mechanism for this weight-reducing effect is unknown, the proposed mechanism includes altered perception of taste due to carbonic anhydrase activity and modulation of dopamine and serotonin levels in the brain [241, 244, 245]. Empatic has shown promising results in phase 2 clinical trials [241] (Table 2). Phase 2 trials demonstrated that patients completing 24 weeks of empatic360 (bupropion SR 360 mg/zonisamide SR 360 mg) and empiratic-120 (bupropion 360 mg/zonisamide 120 mg) therapy attained a significant weight loss as compared to placebo (9.9%, 7.7% vs. 1.7%, respectively (p<0.001)). In the empiratic-360 group, 82.6% of patients lost at least 5% of their baseline body weight and 47.7% lost at least 10% of their baseline body weight as compared to 18.9% and 5.7% patients in the placebo group, respectively [192].

Phenteramine and Topiramate (Qnexa)

 Qnexa is a combination drug that consists of low doses of phentermine and topiramate. Phentermine is a popular appetite suppressant used for weight loss. Topiramate is approved as an anti-epileptic and antimigraine drug having multifactorial effects on the central nervous system. It is thought to act as a γ-aminobutyric acid agonist that increases satiety, although the precise mechanism of action is unclear. Qnexa has shown promising clinical data in a phase 3 trial [246]. An average weight loss of -8.1 kg and -10.2 kg was attained at the end of 56 weeks with phentermine 7.5 mg plus topiramate 46-0 mg, and phentermine 15.0 mg plus topiramate
92.0 mg, respectively. Also, there were significant improvements in cardiovascular and metabolic risk factors among patients treated with Qnexa [246]. An FDA panel recently voted against the NDA of Qnexa because of safety concerns (Table 3). The potential benefits of the drug were overridden by its adverse effect profile, which includes its teratogenic potential, ability to increase heart rate, and propensity to cause psychiatric problems [247].

**Pramlintide and Metreleptin**

This combination targets the long-term adiposity signals (e.g., leptin) and short-term satiety signals (e.g., amylin). This is a novel integrated neurohormonal strategy recently employed for obesity drug development. Various preclinical and clinical studies have demonstrated a synergistic effect of amylin and leptin combination in reducing food intake and body weight [47]. Amylin has also been implicated in enhancing leptin signaling [47]. The combination of the amylin analogue pramlintide and the recombinant human leptin metreleptin caused significant weight reductions (11.5 ± 0.9 kg) in comparison with monotherapy in a 24-week phase 2 clinical trial [248]. The pramlintide/metreleptin combination was well tolerated. The most common side effects were mild-to-moderate adverse events at the injection site and nausea. This combination therapy had completed phase 2 trials successfully. However, the further clinical development of pramlintide/metreleptin combination therapy has been discontinued by the manufacturing companies because of safety concerns [249](Table 3).

**CONCLUSION**

While the development of antiobesity drugs continues to look challenging, researchers retain the hope that effective and safe medications might be on the horizon. A number of drug candidates and targets are currently being explored. Liraglutide, cetilistat, and tesofensine are already in late phases of clinical development. Thus, notwithstanding the existing skepticism about the future development of these drugs, substantial optimism persists that new antiobesity drugs will be available in the foreseeable future.

**CONFLICT OF INTEREST**

The author confirms that this article content has no conflicts of interest.

**ACKNOWLEDGEMENTS**

Declared none.

**REFERENCES**

[1] World Health Organization. Unhealthy diets and physical inactivity. The problem. Available from: http://www.who.int/nmh/publications/fact_sheet_diet_en.pdf. Accessed on September 9, 2011

[2] Allison DB, Fontaine KR, Manson JE, Stevens J, Van Itallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999;282(16):1530-8.

[3] National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(suppl 2):S51-S210.

[4] Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303(3):235-41.

[5] Morton BJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443(7109):289-95.

[6] Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337–350

[7] Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007;117(1):13-23.

[8] Chiesi M, Huppertz C, Hofbauer KG. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol Sci 2001;22(5):247-54.

[9] Field BC, Chandhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 2009;68(6):830-43.

[10] Clapham JC, Arch JR, Tadayon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 2001;89(1):81-121.

[11] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its homologue. Nature 1994;372(6505):425-32.

[12] Dallongeville J, Fruchart JC, Auwerx J. Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. J Med Chem 1998;41(27):5337-52.

[13] Frühbeck G. Intracellular signalling pathways activated by leptin. Biochim J 2006;393(Pt 1):7-20.

[14] Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282(16):1568-75.

[15] Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev 2006;27(7):779-93.

[16] Veniant MM, leBel CP. Leptin: from animals to humans. Curr Pharm Des 2003;9(10):811-8.

[17] Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009;297(6):E1247-59.

[18] El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000;105(12):1027-32.

[19] Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 2007;47:565-92.

[20] Weigle DS. Pharmacological therapy of obesity: past, present, and future. Clin Endocrinol Metab 2003;88(6):2462-9.

[21] Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;1:18.

[22] Bhasin S, Wallace W, Lawrence JB, et al. Metformin treatment and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[23] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[24] Frühbeck G. Intracellular signalling pathways activated by leptin. Biochim J 2006;393(Pt 1):7-20.

[25] Holdren C. Amphetamines: tighter controls on the horizon. Science 1994;266:93.

[26] Liu M, Cheung BM. Pharmacotherapy for obesity. Br J Clin Pharmacol 2003;56(6):1093.

[27] Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1999;23(1):160-3.

[28] Bhasin S, Wallace W, Lawrence JB, et al. Metformin treatment and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[29] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[30] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[31] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[32] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[33] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[34] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.

[35] Kernan WN, Viscoli CM, Brass LM, et al. Angiotensin-converting enzyme inhibitors and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):93.
the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-61.

[36] Schneider R, Golzman B, Turkot S, Kogan J, Oren S. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005; 330(1): 157-60.

[37] Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005; 11(3): 118-23.

[38] Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142(7): 525-31.

[39] Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 2001; 50(8): 889-93.

[40] Rosenbaum M, Goldsmith R, Bloomfield D et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115(12): 3579-86.

[41] MacLean PS, Higgins JA, Johnson GC et al. Enhanced metabolic efficiency contributes to weight regain after weight loss in obesity-prone rats. Am J Physiol Regul Integr Comp Physiol 2004; 287(6): R1306-15.

[42] Breslow MJ, Min-Lee K, Brown DR, Chacko VP, Palmer D, Berkowitz DE. Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol 1999; 276(3 Pt 1): E443-9.

[43] Farooqi IS, Matese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110(8): 1093-103.

[44] Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low-dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002; 87(5): 2391-4.

[45] Novakovic ZM, Leinung MC, Lee DW, Grasso P. Intranasal administration of mouse [D-Leu-4]OBS, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept 2009; 154(1-3): 107-11.

[46] Otvos L, Jr, Terrasi M, Cascio S, et al. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochem Biophys Acta 2008; 1783(10): 1745-54.

[47] Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105(20): 7257-62.

[48] Talbott ME, Langefeld CD, Ziegler J, et al. Polymorphisms near SOC3S are associated with obesity and glucose homeostasis traits in Hispanic Americans from the Insulin Resistance Atherosclerosis Family Study. Hum Genet 2009; 125(2): 153-62.

[49] Chiesa C, Lecureur C, Dechaume A, et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet 2006; 7: 44-54.

[50] Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjørbaek C, Flier JS. Phenotypes in the French population. BMC Med Genet 2006; 7: 147-51.

[51] Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003; 12(2): 223-33.

[52] Lantz KA, Hart SG, Planey SL, et al. Inhibition of PTP1B by Trodusquemine (MSI-1436) Causes Fat-specific Weight Loss in Diet-induced Obese Mice. Obesity (Silver Spring) 2010; 18(8): 1516-23.

[53] Cali AR, Lorraine Tung WC, Pro-opiomelanocortin (POMC) derived peptides and the regulation of energy homeostasis. Mol Cell Endocrinol 2009; 300(1-2): 147-51.

[54] Barb CR, Robertson AS, Barrett JB, Knaeling RR, Houseknecht KL. The role of melanocortin-3 and -4 receptor in regulating appetite, energy homeostasis and neuroendocrine function in the pig. J Endocrinol 2004; 181(1): 39-52.

[55] Masuzaki H, Tanaka T, Ebihara K, Hosoda K, Nakao K. Energy homeostasis regulated by an adipocyte-derived hormone—mechanism of leptin resistance and role of hypothalamic melanocortin signaling. Nippon Rinsho 2009; 67(2): 287-96.

[56] Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88(1): 131-41.

[57] Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106(2): 253-62.

[58] Ni XP, Butler AA, Cone RD, Humphreys MH. Central receptors modulating the cardiovascular actions of melanocyte stimulating hormones. J Hypertens 2006; 24(11): 2239-46.

[59] Giuliano F. Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives. J Androl 2004; 25(5): 683-91.

[60] Deboer MD, Marks DL. Cachexia: lessons from melanocortin antagonism. Trends EndocrinolMetab 2006; 17(5): 199-204.

[61] Lee Z, Wardlaw SL. The central melanocortin system and the regulation of energy balance. Front Biosci 2007; 12: 3994-4010.

[62] Ye Z, Guo L, Barakat KJ, et al. Discovery and activity of (1R,4S,6R)-N-[[1R]-2-[4-cyclohexyloxy-4-[(1,1-dimethylamino)carbonyl]-1-piperidinyl]-1-[4-(2-fluorophenyl)-2-methyl-1-azacyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett 2005; 15(15): 3501-5.

[63] Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009; 86(6): 659-66.

[64] Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16(1): 51-9.

[65] Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142(8): 3292-301.

[66] Vos TJ, Caracotti A, Che JL, et al. Identification of 2-[2-[2-(4-bromo-2-methoxyphenyl)-ethyl]-3-(4-fluorophenyl)-4,5-dihydro-1H-imidazole (ML0253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 2004; 47(7): 1602-4.

[67] Baskin DG. Single-minded view of melanocortin signaling in energy homeostasis. Endocrinology 2006; 147(10): 4539-41.

[68] Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003; 12(2): 223-33.

[69] Michaud JL, Boucher F, Melnyk A, et al. SIM1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet 2001;10:1465–73.

[70] Kubiakou BM, Holder JL Jr, Tolson KP, Genelli T, Zinn AR, SIM1 haploinsufficiency impairs melanocortin-mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol 2006; 20(10): 2483-92.

[71] Alsien JM, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 2001; 98(8): 4652-7.

[72] Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289(14): 1826-32.
infusion. Am J Physiol Regul Integr Comp Physiol 2002; 282(5): R1368-73.

Fernández-Landí L, Caselini CM. Exenatide trials for the treatment of type 2 diabetes. Medicina (B Aires) 2009; 69(4): 447-57.

DeFronzo RA, Ramer RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-100.

Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-91.

Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1): 275-86.

Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30(6): 1487-93.

Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372(9645): 1240-50.

Parks M, RosebaughC. Weighing risks and benefits of liraglutide—the FDA’s review of a new antiobesity therapeutic. N Engl J Med 2010; 365(9): 774-7.

Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009; 49 (Suppl 1): S16-29.

Astrup A, Rössner S, Van Gaal L, et al. Subcutaneous exenatide: 1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374(9701): 1606-16.

Neary MT, Batterham RL. Gut hormones; implications for the treatment of obesity. Pharmacol Ther 2009; 124(1): 44-56.

Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418(6898): 650-4.

Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349(10): 941-8.

Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007; 92(5): 1754-7.

Chen SC, Eiting K, Cui K, et al. Effects of oxyntomodulin supperses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88(10): 4696-701.

Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54(8): 2390-5.

Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese human subjects (randomised) controlled trial. Int J Obes (Lond) 2006; 30(12): 1729-36.

Bloomgarden ZT. Obesity: mediators and treatment approaches. Diabetes Care 2009; 32(5): 48-52.

Mccavigan ak, Murphy Kg. Gut hormones: the future of obesity treatment? Br j clin pharmacol 2012 mar 27. Doi: 10.1111/j.1365-2125.2012.04278.x.

Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006; 361(1471): 1219-35.

Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nonidiabetic humans. Diabetes 1990; 39(6): 752-6.

Lutz ta. Pancreatic amylin as a centrally acting satiating hormone. Curr drug targets 2005; 6(2): 181-9.

Lutz ta, geary n, szabady mm, del prete e, scharrer e. Amylin decreases meal size in rats. Physiol behav 1995; 58(6): 1197-202.
ing: hyperactivity and rapid eye movement sleep suppression. Neur-
osience 2008; 156(4): 819-29.

[166] Haberman AB. Obesity drug pipeline: developing therapies for a
complex disease. Obesity drug pipeline report overview. Insight
Pharma reports. (Published in: September 2008). Available at:
http://www.insightpharareports.com/reports_report.aspx?id=853&
=81176. Accessed on: September 9, 2011.

[167] Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin recep-
tors: a family of hypothalamic neuropeptides and G protein-
coupled receptors that regulate feeding behavior. Cell 1998; 92(4):
573-85.

[168] Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neu-
ropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J
Neurosci 2000; 12(2): 726-30.

[169] Smart D, Sabido-David C, Brough SJ, et al. SB-334867-A: the first
selective orexin-1 receptor antagonist. Br J Pharmacol 2001; 132(6):
1179-82.

[170] Haynes AC, Chapman H, Taylor C, et al. Anorectic, thermogenic and
anti-obesity activity of a selective orexin-1 receptor antagonist in
ob/ob mice. Regul Pept 2002; 104(1-3): 153-9.

[171] Kyrkouli SE, Stanley BG, Leibowitz SF. Galanin: stimulation of
feeding induced by medial hypothalamic injection of this novel
peptide. Eur J Pharmacol 1986; 122(1): 159-60.

[172] Corwin RL, Robinson JK, Crawley JN. Galanin antagonists block
ghrelin-induced feeding in the hypothalamus and amygdala of the
rat. Eur J Neurosci 1993; 5(11): 1528-33.

[173] LeibowitzSF. Differential functions of hypothalamic galanin cell
grow in the regulation of eating and body weight. Ann N Y Acad Sci
1998; 863: 206-20.

[174] Adams AC, Clapham HC, Wynnick D, Speakman JR. Feeding be-
havior in galanin knockout mice supports a role of galanin in fat in-
take and preference. J Neuroendocrinol 2008; 20(2): 199-206.

[175] Smith BK, York DA, Bray GA. Chronic cerebroventricular galanin does not induce sustained hyperphagia or obesity. Peptides 1994;
15(7): 1267-72.

[176] Gundlach AL, Galanin/GALP and galanin receptors: role in central
control of feeding, body weight/obesity and reproduction? J Exp
Pharmacol 2002; 440(2-3): 255-68.

[177] Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE,
Weigle DS, Macdiarmid J. A prepolymerized Olestra product reduces
food intake and body weight gain in mice. Gut 2003; 52(7):
3573

[178] Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither
food intake nor obesity activity of a selective orexin-

[179] Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, anti-
diabetic, and lipid lowering effects of the thyroid receptor beta sub-
type selective agonist KB-141 J Steroid Biochem Mol Biol 2008;
111(3-5): 262-7.

[180] Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hor-
monal receptor agonist GC-1 on metabolic rate and cholesterol in
rats and primates: selective actions relative to 3,5,3'-triiodo-L-
thyronine. Endocrinology 2004; 145(4): 1656-61.

[181] Ng FM, Sun J, Sharma L, Labinaka R, Jiang WJ, Gianello R. Meta-
Bolic studies of a synthetic lipolytic domain (AOD9604) of human
growth hormone. Horm Res 2000; 53(6): 274-8.

[182] Valentino MA, Lin JE, Waldman SA. Central and peripheral mol-
ecular targets for antiobesity pharmacotherapy. Clin Pharmacol
Ther 2010; 87(6): 652-62.

[183] Arch JR, Ainsworth AT, Cawthorne MA, et al. Atypical beta-
adrenoceptor on brown adipocytes as target for anti-obesity drugs.
Nature 1984; 309(5964): 163-5.

[184] Ermoline L, Blin N, Strobsberg AD. The human beta 3-adrenoceptor:
the search for a physiological function. Trends Pharmacol Sci
1994; 15(1): 3-7.

[185] Weyer C, Gauthier JF, Danforth E Jr. Development of beta 3-
adrenoceptor agonists for the treatment of obesity and diabetes--an
update. Diabetes Metab 1999; 25(1): 11-21.

[186] Ito M, Grujic D, Abel ED, et al. Mice expressing human but not
murine beta3-adrenergic receptors improve glucose tolerance, su-
thecese receptors overexpression of the human gene regulatory elements. Diabetes 1998; 47(9): 1464-71.

[187] Connacher AA, Bennet WM, Jung RT. Clinical studies with the
beta-adrenoceptor agonist BRL 26830A.Am J Clin Nutr 1992;
55(Suppl1): 258S-261S.

[188] Wheeldon NM, McDevitt DG, Lipworth BJ. Cardiac effects of the
beta 3-adrenoceptor agonist BRL35155 in man.Br J Clin Pharma-
ocol 1994; 37(4): 363-9.

[189] Cypess AM, Lehman S, Williams G, et al. Identification and im-
portance of brown adipose tissue in adult humans. N Engl J Med
2009; 360(15): 1509-17.

[190] Weyer C, Tataranni PA, Snitker S, Danforth E Jr, Ravussin E.
Increase in insulin action and fat oxidation after treatment with CL
316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998; 47(10): 1555-61.

[191] Sum FW, Gilbert A, Venkatesan AM, et al. Prodrugs of CL316243:
a selective beta3-adrenergic receptor agonist for treating obesity
and diabetes. Bioorg Med Chem Lett 1999; 9(14): 1921-6.

[192] Farrigan c, Peng k. Obesity market overview. Nat Rev Drug Dis-
cov 2002; 1(4): 257-8.

[193] Klingenberg M, Huang SG. Structure and function of the uncou-
pling protein from brown adipose tissue. Biochim Biophys Acta
1999; 1415(2): 271-96.

[194] Boss O, Hagen T, Lowell BB. Uncoupling proteins 2 and 3: poten-
tial regulators of mitochondrial energy metabolism. Diabetes 2000;
49(2): 143-56.

[195] Argyropoulos G, Brown AM, Willi SM, et al. Effects of mutations
in the human uncoupling protein 3 gene on the respiratory quoti-
ent and fat oxidation in severe obesity and type 2 diabetes. J Clin
Invest 1998; 102(7): 1345-51.

[196] Clapham JC, Arch JR, Chapman H, et al. Mice overexpressing
human uncoupling protein-3 in skeletal muscle are hyperphagic and
lean. Nature 2000; 406(6794): 415-8.

[197] Matsuda D, Tomoda H. DGAT inhibitors for obesity. Curr Opin
Investig Drugs 2007; 8(10): 836-41.

[198] Chen HC, Farese RV Jr. DGAT and triglyceride synthesis: a new
target for obesity treatment?. Trends Cardiovasc Med 2000; 10(5):
188-92.

[199] Zhao G, Souers AJ, Voorbach M, et al. Validation of diacylgly-
cerolacyltransferase I as a novel target for the treatment of obesity
and dyslipidemia using a potent and selective small molecule in-
hibitor. J Med Chem 2008; 51(3): 380-3.

[200] Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug
target for obesity treatment. Obes Rev 2005; 6(2): 169-74.

[201] Dobrzyn A, Ntambi JM. The role of stearoyl-CoA desaturase in the
control of metabolism. Prostaglandins Leukot Essent Fatty Acids
2005; 73(1): 35-41.

[202] Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic en-
zyme and attractive target for drug discovery. Cell Mol Life Sci
2005; 62(16): 1784-803.
Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30(5): 234-9.

Bredella MA, Torriani M, Ghomi RH, et al. Adiponectin Is Inversely Associated With Intramyocellular and Intrahepatic Lipids in Obese Premenopausal Women. Obesity (Silver Spring) 2011; 19(5): 911-6.

Liu YL, Liang HR, Liu HT, et al. Association of serum adiponectin levels with artherosclerosis and the metabolic syndrome in obese children. J Pediatr Endocrinol Metab 2010; 23(8): 743-51.

Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-9.

Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipatrophy and obesity. Nat Med 2000; 7(8): 941-6.

Yamauchi T, Hara K, Kubota N, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3(4): 243-54.

Fruebis J, Tso TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98(4): 2005-10.

Cheetham SC, Jackson HC, Vickers SP, Dickinson K, Jones RB, Heal DJ. Novel targets for the treatment of obesity: a review of progress. Drug Discovery Today: Therapeutic Strategies 2004; 1(2): 227-35.

Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, OwensRJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291(5): E1100-5.

Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63(4): 908-14.

Yamada S. Pleiotropic Effects of ARB in Metabolic Syndrome. Curr Vase Pharmacol 2011; 9(2): 158-61.

Sukhija R, Kakar P, Mehta V, Mehta J. Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension. Am J Cardiol 2006; 98(4): 544-8.

Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36: 146-64.

Muñoz R, Carvajal C, Escalona A, et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg 2009; 19(6): 764-70.

Wang SJ, Birtles S, de Schoolmeester J, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetesologia 2006; 49(6): 1333-7.

Tontozon P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79(7): 1147-56.

Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92(6): 829-39.

Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006; 27(7): 728-35.

Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004; 114(9): 1281-9.

Weindruch R, Walford RL, Fliegel S, Guthrie D. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr 1986; 116(4): 641–54.

Chaudhary N, Pfuger PT. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 2009; 12(4): 431-7.

Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 2008; 9(4): 371-8.

Imai s, Armstrong cm, Kaerberlein m, Guarente L. Transcriptional silencing and longevity protein sir2 is an n6-dependent histone deacetylase. Nature 2000; 403(6771): 795-800.

Van Meter M, Mao Z, Gorbonova V, Seluanov A. Repairing split ends: SIRT6, mono-ADP ribosylation and DNA repair. Aging (Albany NY) 2011; 3(9): 829-35.

Yamamoto H, Schoonjans K, Auwerx J. Siruins functions in health and disease. Mol Endocrinol 2007; 21(8): 1745-55.

Pfuger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 2008; 105(28): 9793-8.

Yeomans MR, Gray RW. Opioid peptides and control of human ingestive behaviour. Neurosci Biobehav Rev 2002; 26(6): 713-2.

Greenway FL, Fujikoa K, Podkowski RA, et al. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376(9741): 595-605.

Jones D. Novel pharmacotherapies for obesity poised to enter market. Nat Rev Drug Discov 2009; 8(11): 833-4.

Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19(1): 110-20.

Pollack A. FDA Declines to Approve Diet Drug. The New York Times. Published on: 1 February, 2011. Available from: http://www.nytimes.com/2011/02/02/business/02drug.html Accessed on: February 26, 2012.

Gadde KM, Franciscey DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289(14): 1820-5.

Supuran CT, Di Fiore A, De Simone G.Continuous anhydride inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008; 13(2): 383-92.

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9774): 1341-52.

Pollack A. FDA Rejects Qnexa, a Third Weight-Loss Drug. The New York Times. Published on: 28 October, 2010. Available from: http://www.nytimes.com/2010/10/29/health/policy/29drug.html Accessed on: September 9, 2011.

Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17(9): 1736-43.

Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011; 11(12): 1677-85.